Immunovant, Inc. (IMVT)

27.27 -0.48 (-1.73%) As of 03:04PM EDT. Market open.

Immunovant, Inc.

320 West 37th Street
6th Floor
New York, NY 10018
United States
(917) 580-3099
https://immunovant.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 164

Key executives

Name	Title	Pay	Exercised	Year born
Dr. Frank M. Torti M.B.A., M.D.	Executive Chairperson of the Board	92.5k	N/A	1979
Dr. Chau Cheng M.B.A., Ph.D.	Vice President of Investor Relations	N/A	N/A	N/A
Mr. Mark S. Levine	Chief Legal Officer & Corporate Secretary	N/A	N/A	1973
Ms. Lauren Schrier M.B.A.	Vice President of Marketing	N/A	N/A	N/A
Ms. Christine Blodgett	Vice President of Human Resources	N/A	N/A	N/A
Dr. Julia G. Butchko Ph.D.	Chief Development Officer	531k	N/A	1971
Mr. Andy Deig	Vice President of Financial Planning & Chief of Staff to the CEO	N/A	N/A	N/A
Dr. Michael Geffner M.B.A., M.D.	Chief Medical Officer	N/A	N/A	N/A
Ms. Julie Kirschling	Senior Vice President of Program & Alliance Management	N/A	N/A	N/A
Ms. Jody Roth M.S., P.M.P.	Senior Vice President of Regulatory Affairs	N/A	N/A	N/A

Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that target the neonatal fragment crystallizable receptor for the treatment of myasthenia gravis, thyroid eye disease, chronic inflammatory demyelinating polyneuropathy, and Graves diseases, as well as warm autoimmune hemolytic anemia. The company is headquartered in New York, New York. Immunovant, Inc. operates as a subsidiary of Roivant Sciences Ltd.

Corporate governance

Immunovant, Inc.’s ISS governance QualityScore as of 1 April 2024 is 10. The pillar scores are Audit: 7; Board: 10; Shareholder rights: 10; Compensation: 8.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.